Jade Biosciences, Inc. - 10-Q Filing

Jade Biosciences, Inc. reports Q3 2025 financial results featuring significant R&D and G&A expenditures alongside complex equity instrument activity.

2 articles from 1 source · updated November 13, 2026, 13:36 UTC

Coverage

• Xenetic Biosciences, Inc. - 8-K Filing SEC EDGAR · November 13, 2026, 13:35 UTC
• Jade Biosciences, Inc. - 10-Q Filing SEC EDGAR · November 13, 2026, 12:29 UTC